Huachansu clinical trials
How each study uses huachansu is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 7
Fudan University (2) · M.D. Anderson Cancer Center (1) · The First Affiliated Hospital of Dalian Medical University (1) · Dongfang Hospital Beijing University of Chinese Medicine (1) · Xinjiang Medical University (1) · Xiaonan Cui (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Huachansu is the comparator. A study of two new drugs counts under both.
- 1Icaritin · Beijing Shenogen Biomedical Co., Ltd
Studies
Open first, then newest update. How each study uses huachansu is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCCCompletedPhase 2Fudan UniversityNCT02647125Written as HuachansuHow we know
- Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver CancerStatus unknownPhase 4The First Affiliated Hospital of Dalian Medical UniversityNCT03843229Written as Cinobufacini injectionHow we know
- A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With AscitesStatus unknownPhase 1Dongfang Hospital Beijing University of Chinese MedicineNCT02530398Written as Cinobufacini InjectionHow we know
- Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell LymphomaStatus unknownPhase 2/3Xinjiang Medical UniversityNCT02871869Written as Cinobufacini TabletsHow we know
- Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine CarcinomaStatus unknownPhase 4Xiaonan CuiNCT02860429Written as Cinobufacini injectionHow we know
- Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPaseStatus unknownPhase 2Fudan UniversityNCT01715532Written as HuachansuHow we know
- Huachansu & Gemcitabine in Pancreatic CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT00837239Written as HuaChanSuHow we know
As the comparator · 1 — what is tested is compared with huachansu
- Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)RecruitingPhase 3Beijing Shenogen Biomedical Co., LtdNCT05594927Written as HuachansuHow we know